Novartis’ phase III QUARTZ study of new investigational inhaled combination treatment meets primary and key secondary endpoints

This article was originally published here

In this multicenter, randomized, double-blind phase III QUARTZ study (ClinicalTrials.gov Identifier: NCT02892344), once-daily, low dose IND/MF (QMF149) 150/80 Mu g met the primary and key secondary endpoints (trough

The post Novartis’ phase III QUARTZ study of new investigational inhaled combination treatment meets primary and key secondary endpoints appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply